Background: If HIV patients are unconscious or cannot swallow tablets for other reasons, antiretroviral medication is crushed and dissolved prior to administration. Crushing can alter drug exposure, possibly leading to treatment failure, development of resistance or toxicity. Currently, there is no information about crushing of the branded fixed-dose combination of dolutegravir/abacavir/lamivudine (Triumeq V R , referred to as TRI); therefore, crushing of TRI is not recommended.
Introduction
The HIV-1 integrase inhibitor dolutegravir is marketed as a single tablet (Tivicay V R ) and in a fixed-dose combination tablet with abacavir and lamivudine (Triumeq V R , referred to as TRI). TRI is the largest currently available once-daily fixed-dose combination tablet, possibly causing adherence issues in young adolescents and in patients with comorbidities that affect swallowing. 1 Liquid oral formulations could be an alternative; however, no commercial oral solution is available for dolutegravir and oral solutions for lamivudine (10 mg/mL, 240 mL/bottle) and abacavir (20 mg/mL, 240 mL/ bottle) are not practical to use in adults because of the high volume per dose, and the taste is unpleasant.
If HIV-infected patients are critically ill or are unable to swallow tablets for other reasons, antiretroviral medication is often crushed and suspended to ease administration. Depending on the biopharmaceutical characteristics of a drug and its formulation, crushing tablets can influence drug pharmacokinetics (PK). It may shorten the time to reach maximum plasma concentration, as the gastric disintegration phase does not occur, or change bioavailability and the maximum plasma concentration (C max ). This has been shown for tenofovir, efavirenz and lopinavir, for example. [2] [3] [4] In addition, a PK interaction between dolutegravir and enteral nutrition is likely to occur on the level of absorption. This assumption is based on the known interaction between dolutegravir and cations in antacids, multivitamins and dietary supplements. Simultaneous oral ingestion of antacids, multivitamins, calcium or iron supplements and dolutegravir was shown to decrease C max and AUC of dolutegravir by 33%-74%. 5, 6 Data on crushing elvitegravir fixed-dose combination tablets could not demonstrate an As altered drug exposure may possibly lead to treatment failure, development of resistance or toxicity, therapeutic drug monitoring is currently recommended or the crushing of TRI is advised against due to a lack of data on PK. Therefore, the aim of this study was to investigate whether crushed and suspended TRI and crushed and suspended TRI with enteral nutrition are bioequivalent to taking TRI as a whole tablet.
Patients and methods
This open-label, three-period, randomized, single-dose, crossover trial in healthy adult volunteers was conducted in April 2016 at Radboud university medical center, Nijmegen, the Netherlands.
Ethics
The protocol was approved by the local Ethics Committee of ArnhemNijmegen (reference number and has been registered at ClinicalTrials.gov (NCT02569346). All subjects provided written informed consent prior to study assessments.
Patients
Healthy volunteers that were eligible for inclusion had to be between 18 and 55 years of age, had to weigh at least 40 kg with a BMI of 18.5-30 kg/m 2 , had to be able and willing to sign the Informed Consent Form prior to screening evaluations, had to be in good age-appropriate health condition and not have smoked more than 10 cigarettes per day for at least 3 months prior to day 1. Main exclusion criteria were: positive test for HIV, hepatitis B or hepatitis C; positive HLA-B*5701 status; sensitivity/idiosyncrasy to medicinal products or excipients; relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion; pregnant female; therapy with any drug except for acetaminophen; abuse of drugs, alcohol or solvents; gluten-free diet; participation in a drug study; recent donation of blood; and febrile illness.
Methods
The study was designed to demonstrate bioequivalence between wholetablet TRI with 200 mL of water (reference treatment) and a crushed and suspended TRI tablet with 200 mL of water (intervention I) and a crushed and suspended TRI tablet with 200 mL of water combined with oral intake of 250 mL (1 kcal/mL) of Nutrison enteral nutrition (Nutricia, Zoetermeer, the Netherlands) (intervention II). Two hundred and fifty millilitres of Nutrison contains 9.75 g of fat, 4 mg of iron, 3 mg of zinc, 200 mg of calcium and 57.5 mg of magnesium. Tablets were crushed with a tablet crusher; 'narrow' type (Hammarplast Medical AB, Lidköping, Sweden). Subjects randomly received a single dose of the reference or intervention treatments, with a washout period of 7 days.
Power calculation was performed by using a mixed linear model with period and treatment as fixed factors. A total sample size of 18 evaluable subjects was considered sufficient for a power of 80% in the case of bioequivalence. Twenty-two subjects were included to account for possible dropouts.
PK curves were collected on day 1, 8 and 15 at the following timepoints: t " 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after ingestion. Dolutegravir, abacavir and lamivudine plasma concentrations were analysed using an internally and externally validated ultra-performance LC MS method (LC-MS/MS). 8 The lower limit of quantification (LLOQ) for dolutegravir, abacavir and lamivudine was 0.01 mg/L, 0.0149 mg/L and 0.0150 mg/L, respectively. PK parameters were determined using a non-compartmental analysis in WinNonlin (version 6.3, Pharsight Corporation, St Louis, USA). Geometric mean ratios (GMRs) with 90% CI of AUC 0-1 and C max were calculated for interventions I and II versus the reference treatment after log transformation of within-subject ratios using a fixed-effects bioequivalence module in WinNonlin/Phoenix. Two treatments were considered bioequivalent if the 90% CI of the GMR of AUC 0-1 and C max fell within 80%-125%. 9 Furthermore, safety and tolerability of a single-dose crushed and suspended TRI tablet with or without enteral nutrition was evaluated. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE).
Results
Twenty-two healthy adult volunteers (55% male, 91% white and 9% of mixed race) were enrolled in this study, all of whom completed the study. The median (range) age was 25 (18-54) years and median (range) BMI was 23 (20-27) kg/m 2 . Figure 1 shows the mean plasma concentration versus time profiles of all compounds for each treatment. Table 1 shows the PK parameters for dolutegravir, abacavir and lamivudine of the reference treatment, intervention I and intervention II, and GMRs of both interventions versus the reference treatment. Dolutegravir plasma concentrations for intervention I (crushed and suspended TRI tablet with fasting) were 26% higher compared with the reference treatment (whole-tablet TRI with fasting). Dolutegravir C max increased by 30% compared with the reference treatment. Bioequivalence between intervention I and the reference treatment could not be demonstrated as the GMR with 90% CI for AUC 0-1 and C max of dolutegravir fell outside the required limits of 80%-125%. For abacavir and lamivudine, all 90% CIs fell within the bioequivalence limits of 80%-125%.
After intake of a crushed and suspended TRI tablet with enteral nutrition (intervention II), dolutegravir plasma concentrations increased by 18% compared with the reference treatment. Dolutegravir C max was 22% higher and abacavir C max was 17% lower compared with the reference treatment. The 90% CIs of the GMRs for C max of both dolutegravir and abacavir, comparing a crushed and suspended TRI tablet with enteral nutrition with whole-tablet TRI, fell outside the predefined bioequivalence range. All other 90% CIs fell within the required limits of 80%-125%.
No serious adverse events were reported during the trial. In 77% of the healthy adult volunteers one or more adverse event was observed and reported. Of the reported adverse events, 25/53 (47%) were judged to be probably or possibly related to TRI and the most frequently reported were headache (24%, grade 1-2), nausea (16%, grade 1), fatigue (16%, grade 1) and dizziness, abdominal pain and diarrhoea (all 12%, grade 1). There was one case of difficulty in falling asleep and one case of elevated amylase (both grade 1). All related adverse events were resolved or resolving at the end of the study.
Discussion
This study shows that crushing and suspending TRI leads to higher dolutegravir exposure (AUC) and C max . Bioequivalence could not be
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V R JAC demonstrated for a crushed and suspended TRI tablet, either under fasting conditions or combined with enteral nutrition, compared with whole-tablet TRI. One case report was published on an antiretroviral-naive patient who crushed tenofovir disoproxil fumarate/emtricitabine and dolutegravir tablets on his own initiative and mixed them with apple sauce. This patient achieved virological suppression after 4 weeks of treatment with good tolerability. This case report suggests effectiveness of crushed and Roskam-Kwint et al.
suspended dolutegravir. 10 Our data show higher dolutegravir levels reached after crushing, which supports the sustained effectiveness seen in this case report. As the t1 =2 for dolutegravir was similar in all treatments, the increased dolutegravir exposure is probably caused by enhanced absorption.
In our opinion, the increased dolutegravir exposure we observed in this study is not clinically relevant in terms of safety, because dolutegravir exposure is even higher if taken with food 11, 12 or in twice-daily dosing, which is recommended in patients with HIV-1 with resistance to other integrase inhibitors. 13 Besides the effect of crushing and the known effect of food, an interaction between dolutegravir and cations in enteral nutrition is likely to occur. Simultaneous intake with antacids and cationcontaining supplements is advised against due to decreased exposure and C max of dolutegravir; however, this effect is attenuated when taken with food. 6 This study, though, shows that fasting intake of crushed TRI with oral intake of enteral nutrition, which is considered a high-fat liquid, increases dolutegravir exposure. This is in line with results for crushed elvitegravir fixed-dose combination tablets (Stribild V R ) taken with enteral nutrition. 7 Therefore, we assume that the effect of crushing and intake with enteral nutrition sufficiently counteracts the possible negative effect on dolutegravir absorption by cations.
Furthermore, decreased abacavir C max after crushing and suspending TRI combined with enteral nutrition is similar to results from other studies of abacavir taken with food and considered not clinically relevant. 11, 14, 15 Lamivudine exposure and C max were bioequivalent to intake of the whole tablet. As a result, it can be concluded that TRI can be crushed and combined with enteral nutrition without separating intake in time.
The combination of a twice-daily dolutegravir dose, intake with food and crushing of dolutegravir altogether, could lead to high plasma concentrations, assuming the maximum absorption has not yet been reached. As data on the relationship between dolutegravir plasma concentrations and toxicity have not yet been fully elucidated, additional monitoring for side effects should be implemented in this situation.
This study did not investigate the effects of feeding tubes; therefore, it is unknown whether absorption would be similar in HIV-seropositive patients with different enteral feeding tubes, e.g. different diameter, different characteristics of the tubing material and other tube exit locations in the gastrointestinal tract. Particular care should be taken with tubes exiting beyond the pylorus. A case report described lower-than-expected dolutegravir concentrations in a patient with dolutegravir (50 mg twice daily) administered via an orogastric tube, when compared with patients administered a 100 mg total daily dose. HIV-1 RNA remained undetectable, but the authors would recommend consideration of dolutegravir dose titration (150-200 mg total daily dose) to achieve optimal dolutegravir trough concentrations via the enteral route, especially in the integrase-experienced patient. 16 In conclusion, bioequivalence could not be demonstrated for a crushed and suspended tablet or a crushed and suspended tablet with oral intake of enteral nutrition compared with whole-tablet TRI with fasting. Both scenarios led to higher dolutegravir exposure, but this did not exceed exposure after intake with food or in twice-daily dosing. In our opinion TRI can be crushed for patients with swallowing difficulties and can be simultaneously administered with enteral nutrition. 
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